Indeed, phenotypic analysis showed that especially CDK (e.g., CDK 1, 2, 5, and 9 inhibitor dinaciclib) and DNA-PK (e.g., DNA-PK and PI3K inhibitor PIK-75) inhibitors induced a novel phenotypic change, characterized by cyst sizes smaller than unstimulated control cysts and loss of cyst integrity, that could indicate a toxic effect, rather than only affecting the size of the cysts. The gene discussed is PRKDC; the disease is cyst.